

## ASX Announcement

**Melbourne, Australia, 5 April 2023**

### Rights Issue Prospectus – Extension of Closing Date

Genetic medicine and exosome-based drug-delivery company Exopharm Limited (ASX:EX1) is undertaking a pro rata non-renounceable entitlement offer on the basis of one new fully paid ordinary share in the Company (**Offer Share**) for every one existing ordinary share in the Company (**Share**) held as at 5:00 pm (AEDT) on 28 March 2023 (**Record Date**) for an issue price of \$0.01 per Offer Share (**Issue Price**) to raise up to \$1.57 million before costs (**Entitlement Offer**).

The Company advises that it has extended the Closing Date of the Entitlement Offer from Thursday 13 April 2023 to Thursday 20 April 2023 owing to the time taken for some shareholders to receive their Entitlement Offer documentation. The amended timetable is set out below:

	23 March 2023
Lodgement of Prospectus	
“Ex” date (existing shares quoted on an ex rights basis)	27 March 2023
Record date to identify shareholders entitled to participate in the Rights Issue ( <b>Record Date</b> ) at 7:00pm (Melbourne time)	28 March 2023
Prospectus dispatched to holders eligible to participate in the Rights Issue	31 March 2023
Rights Issue Closing Date	5.00pm (Melbourne time) on 20 April 2023
Announcement of results of Rights Issue to ASX	28 April 2023
Proposed issue date of New Shares under the Rights Issue	28 April 2023
Shortfall Closing Date	20 July 2023 (three months after the Rights Issue Closing Date)

*The above dates should be regarded as **indicative only and may change without notice**. All dates and times are Melbourne, Victoria, Australia time. Subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws, the Company reserves the right to change the above dates, close the Rights Issue (and consequently the Shortfall Offer and the Broker Options Offer) before the date stated above, extend the Closing Date and consequently the Shortfall Closing Date and subsequent dates, close the Shortfall Offer early, or not proceed with any of the Offers. The Company reserves the right to close any of the Offers, extend the closing date and Shortfall Closing Date or make any other changes to dates by announcement of the extension to ASX.*

*By the Managing Director – this announcement has been authorised for release by the Managing Director.*

[To discuss your entitlement, please contact your Adviser or the Joint Lead Managers below](#)

Craig Brown  
Alto Capital  
(08) 9223 9888  
[craig@altocapital.com.au](mailto:craig@altocapital.com.au)  
[www.altocapital.com.au](http://www.altocapital.com.au)

Paul Hart  
Canary Capital  
0421 051 474  
[phart@canarycapital.com.au](mailto:phart@canarycapital.com.au)  
[www.canarycapital.com.au](http://www.canarycapital.com.au)

### [Company and Media Enquiries:](#)

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

[www.exopharm.com](http://www.exopharm.com)

P: +61 (0)3 9111 0026

Ian Dixon  
Managing Director

Tel: +61 418 561 907  
[ian.dixon@exopharm.com](mailto:ian.dixon@exopharm.com)

### [ABOUT EXOPHARM](#)

Exopharm (ASX:EX1) is a leader in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes.

Exosomes could be an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

### [FORWARD LOOKING STATEMENTS](#)

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.